|
ALNY | Alnylam Pharmaceuticals, Inc. |
|
|
ALNY | Alnylam Pharmaceuticals, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.01 |
| Leverage | 98.03% |
| Market Cap | $ 32.3B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -268.8m |
| Margin | -12.64% |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.